Loading...
XKRX009420
Market cap1.20bUSD
Dec 24, Last price  
34,500.00KRW
1D
1.62%
1Q
-6.25%
Jan 2017
162.36%
Name

Hanall Biopharma Co Ltd

Chart & Performance

D1W1MN
XKRX:009420 chart
P/E
498.63
P/S
12.97
EPS
69.19
Div Yield, %
0.00%
Shrs. gr., 5y
-0.19%
Rev. gr., 5y
7.99%
Revenues
134.91b
+22.65%
82,485,563,00091,890,326,00098,682,408,000106,903,737,00087,701,600,68076,027,305,22074,228,313,77080,879,668,14080,022,559,94082,881,524,07084,230,756,08091,839,350,940108,452,042,40088,602,270,090101,594,443,690109,995,418,980134,909,837,620
Net income
3.51b
+1,295.22%
-1,029,708,0001,170,025,000581,952,000213,659,000-14,525,740,000-2,922,595,000-21,498,897,000-12,658,084,910-7,077,356,9502,026,026,4205,813,253,6603,300,102,19019,174,349,79019,764,498,9208,896,137,170251,473,6403,508,607,550
CFO
29.64b
+17.61%
271,722,000-3,278,652,0004,742,178,0001,418,781,0007,413,981,1002,197,165,680-7,780,098,850-3,518,357,340-454,023,7003,950,368,12042,138,652,270-2,994,392,10020,490,918,610929,290,570839,871,90025,204,350,56029,642,920,050
Earnings
Jan 22, 2025

Profile

Hanall Biopharma Co.,Ltd, a pharmaceutical company, researches, develops, and sells pharmaceutical products in South Korea and internationally. The company offers specialty drugs and over-the-counter products for the treatment of gastric and duodenal ulcers, gastritis, cerebrovascular and peripheral blood vessel disorder, hypertension, atherosclerotic symptom, acute coronary syndrome, atherothrombosis and thromboembolism, diabetes, osteoporosis, chronic kidney failure, hypothyroidism, vitamin D-resistant rickets, osteomalacia, erectile dysfunction, prostatic hyperplasia, candidiasis, various fungal infections, prostate cancer, formal, constipation, thin stools, bloating, bowel abnormal fermentation, and hemorrhoids. The company was founded in 1973 and is based in Seoul, South Korea.
URL
http://www.hanall.co.kr/
IPO date
Dec 18, 1989
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
134,909,838
22.65%
109,995,419
8.27%
101,594,444
14.66%
Cost of revenue
109,503,518
87,758,515
72,247,677
Unusual Expense (Income)
NOPBT
25,406,319
22,236,904
29,346,767
NOPBT Margin
18.83%
20.22%
28.89%
Operating Taxes
(306,075)
1,677,956
(194,047)
Tax Rate
7.55%
NOPAT
25,712,395
20,558,948
29,540,814
Net income
3,508,608
1,295.22%
251,474
-97.17%
8,896,137
-54.99%
Dividends
Dividend yield
Proceeds from repurchase of equity
(9,945,160)
408,716
BB yield
1.10%
-0.04%
Debt
Debt current
700,220
559,343
423,433
Long-term debt
1,880,839
2,061,457
2,246,792
Deferred revenue
14,410,225
15,291,013
11,227,284
Other long-term liabilities
876,219
617,992
(50)
Net debt
(113,542,411)
(53,535,350)
(34,114,472)
Cash flow
Cash from operating activities
29,642,920
25,204,351
839,872
CAPEX
(2,412,125)
(7,676,957)
(9,002,097)
Cash from investing activities
(11,887,229)
(10,592,439)
8,029,663
Cash from financing activities
(813,508)
(10,644,037)
(306,533)
FCF
34,798,970
7,147,045
25,291,694
Balance
Cash
56,497,111
53,934,070
80,569,547
Long term investments
59,626,360
2,222,079
(43,784,849)
Excess cash
109,377,979
50,656,378
31,704,976
Stockholders' equity
84,663,642
73,666,770
58,950,932
Invested Capital
118,131,701
133,899,657
144,254,696
ROIC
20.40%
14.78%
20.50%
ROCE
12.53%
12.05%
16.61%
EV
Common stock shares outstanding
50,692
50,816
51,203
Price
44,300.00
148.88%
17,800.00
-15.44%
21,050.00
-43.87%
Market cap
2,245,655,777
148.27%
904,520,564
-16.08%
1,077,821,129
-43.84%
EV
2,132,390,102
850,985,214
1,043,706,657
EBITDA
28,653,264
25,289,557
32,071,624
EV/EBITDA
74.42
33.65
32.54
Interest
63,863
21,875
25,480
Interest/NOPBT
0.25%
0.10%
0.09%